Sotera Health Co - SHC STOCK NEWS

Nelson Labs, a Sotera Health company, has launched Rapid Sterility Testing services at three laboratory sites across the United States and Europe. This innovative testing method reduces product sterility test results time from the traditional 14-day period to as little as 6 days, while maintaining compliance with USP <71> and <1223> standards.

The new testing solution uniquely supports both medical device and pharmaceutical products, expanding beyond the typical focus on biological components or short shelf-life products. The method employs quantitative data instrumentation to automate test results, reducing human error potential. This advancement enables faster product release while maintaining quality and safety standards.

Sotera Health (Nasdaq: SHC) reported its Q4 and full-year 2024 results, showing mixed performance. Full-year 2024 highlights include:

- Net revenues increased 4.9% to $1.10 billion
- Net income of $44 million ($0.16 per diluted share)
- Adjusted EBITDA grew 3.9% to $549 million

However, Q4 2024 showed some weakness:
- Net revenues decreased 6.5% to $290 million
- Net income dropped to $12 million ($0.04 per diluted share)
- Adjusted EBITDA declined 8.3% to $153 million

For 2025 outlook, the company projects:
- Net revenues growth of 4.0% - 6.0%
- Adjusted EBITDA growth of 4.5% - 6.5%
- Adjusted EPS range of $0.70 to $0.76

Sotera Health Company (Nasdaq: SHC), a leading global provider of sterilization solutions and lab testing services for the healthcare industry, has scheduled its fourth-quarter and full-year 2024 financial results release for Thursday, February 27, 2025, before market opening.

The company will host a conference call at 9:00 a.m. Eastern Time to discuss operating highlights and financial results. Participants can join by dialing 1-844-481-2916 (US) or 1-412-317-0709 (international locations). A live webcast and accompanying materials will be accessible through the company's Investor Relations website, with a replay available later that day.

Sotera Health (Nasdaq: SHC) presented at the 43rd Annual J.P. Morgan Healthcare Conference, where Chairman and CEO Michael B. Petras, Jr. provided a business update. The company, a leading provider of sterilization solutions and lab testing services for the healthcare industry, expects to report full-year revenues of approximately $1.1 billion for 2024, representing nearly 5% growth compared to 2023 and over 5% growth on a constant currency basis.

The company's management team, including CFO Jon Lyons and VP of Investor Relations Jason Peterson, are participating in investor meetings during the conference. A live webcast of the presentation is available on the company's website, with a replay to be archived. Full 2024 financial results and 2025 outlook will be reported on February 27, 2025.

Sotera Health Company (NASDAQ: SHC), a leading global provider of sterilization solutions, lab testing, and healthcare advisory services, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Chairman and CEO Michael B. Petras, Jr. will deliver a presentation on Tuesday, January 14, 2025, at 11:15 a.m. Eastern Time.

The company's senior leadership team, including CFO Jon Lyons and VP of Investor Relations Jason Peterson, will engage in investor meetings throughout the conference. Investors and interested parties can access a live webcast of the presentation through Sotera Health's Investor Relations website section under Presentations & Events. The presentation materials will be available for viewing, and a replay will be accessible within 48 hours after the conference concludes.

Sotera Health Company (Nasdaq: SHC) has appointed Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Petrella, who has been serving on the company's Board of Directors since 2020, will act as a key liaison among the Board, management, and shareholders.

The appointment leverages Petrella's decades of public company executive leadership and board experience, including his role as chairperson of Sotera Health's Audit Committee. Michael B. Petras, Jr., Sotera Health Chairman and CEO, highlighted Petrella's valuable experience, insight, and engagement since joining the Board.

Firstlight Management LP, a shareholder of Sotera Health Company (SHC), has sent a letter to the Board of Directors urging the sale of its Nelson Labs subsidiary. The investment firm argues that Nelson Labs has underperformed with a mere 2.7% EBITDA CAGR over 2018-2024E, significantly lower than Sterigenics (9.8%) and Nordion (8.2%). The proposed sale could generate approximately $1.1bn in gross proceeds at a 15.2x EBITDA multiple, potentially reducing SHC's net leverage ratio from 3.7x to 2.2x on 2024E EBITDA. The transaction could result in ~13% lift to 2025E EPS and allow management to focus on core sterilization businesses.

Sotera Health Company (Nasdaq: SHC) announced its 2024 Investor Day in New York City, where management will present the company's strategic positioning and future growth plans. The company, which provides sterilization solutions and lab testing services, will outline its 2025-2027 financial plan targeting 5-7% organic revenue growth, 5-8% Adjusted EBITDA growth, and over $500 million in cumulative Free Cash Flow. Management will discuss their $18 billion serviceable addressable market and demonstrate the company's strength while fulfilling its Safeguarding Global Health® mission.

Sotera Health (SHC) reported strong Q3 2024 financial results with net revenues increasing 8.5% to $285 million. The company achieved net income of $17 million ($0.06 per diluted share), compared to a net loss of $14 million in Q3 2023. Adjusted EBITDA grew 9.0% to $146 million.

Year-to-date performance showed net revenues up 9.6% to $810 million, with net income of $32 million. All three business segments - Sterigenics, Nordion, and Nelson Labs - reported revenue growth. The company reaffirmed its 2024 outlook for net revenues and Adjusted EBITDA growth of 4.0% to 6.0%.